elminda is Leading the Neural Revolution
540,000 standardized datasets and growing
Total addressable market in the US alone
Patents with innovation treatment opportunities
Driving Innovation with elminda Data Platform
BNA™ Technology provides a flywheel effect that drives further growth & market offerings as the dataset grows.
- Grows database with each new patient
- Builds clinical insight
- Develops capability and product opportunities
- Drives application adoption
The commercial launch of BNA™ will further drive data growth and insight, along with topline revenue, with each additional patient.
Leveraging Big Data, Signal Processing, & AI
ROBUST COMPETITIVE ADVANTAGE
elminda has the world’s largest Medical Grade Standardized database of EEG & ERP recordings to provide clinicians with technology to clearly and accurately interpret brain function.
ATTRACTIVE BUSINESS MODEL
Recurring revenue and established reimbursement. Platform built to develop future biomarkers and companion diagnostics allowing for the expansion of existing pharma collaborations and partnerships to bring new drugs to market.
INNOVATIVE TREATMENT OPPORTUNITIES
The first practical and feasible way for front-line clinicians to objectively measured and compare brain function (cognition). The elminda Data Platform is FDA cleared(510k) & CE marked software platform with over 7 years of clinical experience and $75M capital invested.
elminda Data Platform, powered by BNA™ technology, is the world’s largest Medical Grade standardized database with near-limitless potential growth.
Drug Therapy Development
Executive and Private Health Programs
Improving Patient Care Outcomes
BNA™ Potential Primary Growth Channels
BNA™ could improve treatment of depression significantly by objectively measuring brain health, improving and saving lives.
BNA™ could identify early on-set of dementia and possibly delay onset through optimised patient care.
3. Pharma Industry
BNA™ can help objectively quantify drug impact and develop patient response models.
Proven Utility Basis for Growth
Extensive previous experience provides tangible future development business opportunities.
Objectively measured drug impact on depression and cognition
Measured effect of Ketamine on the brain of healthy subjects.
Objective assessment of network dynamics activated by pain.
Developed composite Memory Score for early detection of MCI & Dementia
Predicted treatment outcome with TMS
Clinical Practice: Dementia
Cognitive decline objectively measured before self-reported symptoms
Clinical Practice: Depression
Improved patient compliance to TMS therapy; objective measure on therapy impact
We Invite You To Learn More
The neural revolution is multi-layered, complex and exciting – but it requires in-depth discussion and analysis of our go-to-market strategy, technology and data leadership. We encourage institutional investors to book time with our leadership team for a proper investor presentation.